Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nurix Therapeutics (NRIX – Research Report), Tarsus Pharmaceuticals (TARS – Research Report) and TG Therapeutics (TGTX – Research Report).
Nurix Therapeutics (NRIX)
Wells Fargo analyst Derek Archila maintained a Buy rating on Nurix Therapeutics on October 13 and set a price target of $23.00. The company’s shares closed last Friday at $6.37, close to its 52-week low of $5.92.
According to TipRanks.com, Archila is a 4-star analyst with an average return of
Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $26.33, a 312.1% upside from current levels. In a report issued on October 13, Robert W. Baird also maintained a Buy rating on the stock with a $24.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Tarsus Pharmaceuticals (TARS)
In a report issued on October 13, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Tarsus Pharmaceuticals, with a price target of $46.00. The company’s shares closed last Friday at $12.98, close to its 52-week low of $11.33.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tarsus Pharmaceuticals with a $48.00 average price target.
TG Therapeutics (TGTX)
In a report issued on October 13, Alec Stranahan from Bank of America Securities maintained a Sell rating on TG Therapeutics, with a price target of $6.00. The company’s shares closed last Friday at $6.69, close to its 52-week low of $4.86.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
TG Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $23.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NRIX:
- Nurix Therapeutics price target lowered to $24 from $31 at Baird
- Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
- Nurix Therapeutics price target raised to $35 from $33 at H.C. Wainwright
- Cathie Wood’s ARK Investment bought 341.3K shares of Nurix Therapeutics today
- Nurix Therapeutics partners with Seagen to develop cancer therapeutics
